Aortic Valve Disease and Associated Complex CAD: The Interventional Approach

Federico Marin 1, Roberto Scarsini 2, Rafael A. Kotronias 1, Dimitrios Terentes Printzios 1, Matthew K. Burrage 1, Jonathan J. H. Bray 3, Jonathan L. Ciofani 4, Gabriele Venturi 2, Michele Pighi 2, Giovanni L. De Maria 1 and Adrian P. Banning 1,

1 Oxford Heart Centre, Oxford University Hospitals, NHS Trust, Oxford OX3 9DU, UK; federicomarin@alice.it (F.M.); rafail.kotronias@cardio.ox.ac.uk (R.A.K.); dimitrios.terentes-printzios@ouh.nhs.uk (D.T.P.); matthew.burrage@ouh.nhs.uk (M.K.B.); giovanniluigi.demaria@ouh.nhs.uk (G.L.D.M.)
2 Department of Cardiology, University of Verona, 37129 Verona, Italy; scarsini.roberto@gmail.com (R.S.); gabriele.venturi.vr@gmail.com (G.V.); michele.pighi@univr.it (M.P.)
3 Institute of Life Sciences 2, Swansea Bay University Health Board and Swansea University Medical School, Swansea SA2 SQA, UK; Jonathan.Bray@wales.nhs.uk
4 Department of Cardiology, Royal North Shore Hospital, Sydney 2065, Australia; ciofani.jc@gmail.com

Abstract: Coronary artery disease (CAD) is highly prevalent in patients with severe aortic stenosis (AS). The management of CAD is a central aspect of the work-up of patients undergoing transcatheter aortic valve implantation (TAVI), but few data are available on this field and the best percutaneous coronary intervention (PCI) practice is yet to be determined. A major challenge is the ability to elucidate the severity of bystander coronary stenosis independently of the severity of aortic valve stenosis and subsequent impact on blood flow. The prognostic role of CAD in patients undergoing TAVI is being still debated and the benefits and the best timing of PCI in this context are currently under evaluation. Additionally, PCI in the setting of advanced AS poses some technical challenges, due to the complex anatomy, risk of hemodynamic instability, and the increased risk of bleeding complications. This review aims to provide a comprehensive synthesis of the available literature on myocardial revascularization in patients with severe AS undergoing TAVI. This work can assist the Heart Team in individualizing decisions about myocardial revascularization, taking into account available diagnostic tools as well as the risks and benefits.

Keywords: aortic stenosis; coronary artery disease; myocardial revascularization; percutaneous coronary intervention

1. Introduction

Aortic stenosis (AS) is the most common heart valve disease and is frequently associated with coronary artery disease (CAD). Recent multi-center trials report a high prevalence (~60%) of significant coronary stenosis among patients undergoing transcatheter aortic valve implantation (TAVI) [1,2]. The strong association between the two conditions is primarily due to an ensemble of clinical and genetic risk factors shared by both diseases including age, smoking, hypertension and hyperlipidemia [3]. The management of CAD is a central aspect of the work-up for TAVI, but the evidence available is still limited and the best percutaneous coronary intervention (PCI) practice in TAVI candidates is yet to be determined. A major challenge in patients with severe AS is the ability to elucidate the severity of bystander coronary stenosis independently of the severity of aortic valve disease. Furthermore, PCI in the setting of severe AS poses some technical challenges, including a high burden of complex and often heavily calcified coronary disease, the risk of hemodynamic instability and a potential series of challenges in re-engaging coronary ostia after
TAVI requiring advanced and dedicated skills. An accurate selection of patients who need to undergo valve replacement plus myocardial revascularization is, therefore, paramount.

2. Anatomical CAD Assessment in AS

2.1. Coronary Angiogram

Coronary angiogram is the first line method for the assessment of coronary artery anatomy. According to the 2017 ESC Guidelines coronary angiography is recommended before valve surgery in patients with severe aortic stenosis and history of CAD, suspected myocardial ischemia, left ventricular dysfunction, one or more cardiovascular risk factor or in men older than 40-year old or postmenopausal women [4]. The coronary arteries of patients with severe AS are characterized by extensive calcification and tortuosity. Such characteristics reduce the reliability of angiography in the setting of AS, and in turn, hamper our ability to accurately estimate the degree of myocardial ischemia in TAVI patients [5]. In addition, there is only a modest correlation between angiography and intracoronary physiology in AS, especially in the territory of the left anterior descending artery (LAD), where even angiographically mild-moderate lesions may be functionally significant [6].

2.2. Coronary CT Angiography

Contrast enhanced multi-detector computed tomography is pre-operatively performed to assess access route, and to assist with tissue heart valve sizing and other aspects of procedural planning. The role of computed tomography coronary angiography (CTCA) has been assessed and recently recommended for CAD evaluation in these patients, due to the practicality of acquiring ECG-gated coronary phases at the same setting without additional contrast [5].

When using invasive coronary angiography as a reference, the reported sensitivity and negative predictive value (NPV) of CTCA in identifying moderate obstructive CAD (>50% of diameter stenosis) in TAVI patients ranges between 90–100% and 90–96%, respectively (Table 1) [7–11]. Conversely, the specificity and positive predictive value (PPV) are often suboptimal and highly variable, ranging from 37–99%, and 37–95%, respectively (Table 1) [7–11]. A recent meta-analysis on 1275 patients undergoing CTCA and with a CAD prevalence similar to real world patients, showed 95% sensitivity, 65% specificity and 94% NPV; correctly identifying 442 (35%) patients as not having obstructive CAD [7]. The sub-optimal specificity can be largely explained by blooming artifacts and beam hardening due to the high calcium load that the coronary trees exhibit in TAVI candidates [7]. Rossi et al. have shown that increasing calcium score was associated with increased frequency of false positive and false negative results on CTCA and in the subgroup with <400 calcium score, CTCA had better diagnostic performance compared to ≥400 calcium score [12].

| Study            | Study Design                     | Patients (n) | Definition Significant Stenosis | Vessels Evaluated | Sn (%) | Sp (%) | PPV (%) | NPV (%) |
|------------------|----------------------------------|--------------|---------------------------------|-------------------|--------|--------|---------|---------|
| Strong et al. [13]| Retrospective cohort             | 200          | >50% stenosis                   | Native            | 100    | 42     | 48      | 100     |
| Chaikriangkrai et al. [14] | Systematic review and meta-analysis | 1498         | >50% stenosis                   | Native (no stents) | 91     | 99     | 8       | 100     |
| Andreini et al. [8] | Prospective cohort               | 325          | >50% stenosis                   | Native (stented)  | 94     | 87     | 67      | 98      |
| Annoni et al. [15] | Prospective cohort               | 115          | –                               | All               | 97     | 85     | 62      | 99      |
| Rossi et al. [12]  | Prospective Cohort               | 140          | >50% stenosis                   | All               | 91     | 55     | 59      | 90      |
|                  |                                   |              | >70% stenosis                   | All               | 78     | 74     | 37      | 95      |
| Study               | Study Design     | Patients (n) | Definition Significant Stenosis | Vessels Evaluated | Sn (%) | Sp (%) | PPV (%) | NPV (%) |
|--------------------|------------------|--------------|---------------------------------|-------------------|--------|--------|---------|---------|
| Matsumoto et al. [11] | Prospective cohort | 60           | >50% stenosis                    | All               | 92     | 58     | 41      | 91      |
| Hamdan et al. [9]  | Prospective cohort | 115          | >50% stenosis                    | Native CABG       | 93     | 73     | 62      | 96      |
| Opolski et al. [10] | Prospective cohort | 475          | >50% stenosis                    | All               | 100    | 75     | 95      | 100     |
| Harris et al. [16] | Retrospective cohort | 100         | >50% stenosis                    | All               | 98     | 37     | 67      | 94      |
| Chieffo et al. [17] | Retrospective cohort | 491         | –                               | All               | –      | –      | 48      | –       |

Abbreviations: Sn, Sensitivity; Sp, Specificity; PPV, Positive predictive value; NPV, Negative predictive value; CABG, Coronary artery bypass graft.

Nonetheless, a strategy using CTCA to rule out significant obstructive CAD may be still considered, with subsequent reductions in resource utilization and avoidance of exposing patients to the risks of invasive coronary angiography [18]. The outcomes of such a strategy were assessed in a cohort by Chieffo et al., showing that selection of patients following CTCA to undergo invasive coronary angiography either due to a suspicious coronary lesion (76%) or an uninterpretable CTCA (24%) was safe with no harm signal [17]. However, this study was retrospective and prone to selection bias and residual confounding despite attempts for adjustment [17].

3. Functional CAD Assessment in Aortic Stenosis

Symptom onset heralds a worse prognosis in AS and is a key indication for aortic valve replacement [4,19]. However, it is important to accurately determine whether symptoms are due to the valve itself, or co-existing CAD. The presence of chest pain is a poor discriminator, given the competing pathophysiology between hemodynamically significant CAD and severe AS. Angina is a typical prognostically significant symptom of severe AS and occurs frequently in the absence of obstructive CAD [20–22]. Angina in AS, in the absence of significant obstructive CAD is likely due to left ventricular hypertrophy, consequent increased oxygen demand and impaired myocardial perfusion. Microvascular dysfunction has been frequently described and may result from a combination of factors including increased resting flow and consequent reduced coronary flow reserve and extrinsic compression of the microvasculature [21,23,24]. Due to the propensity for ischemia, the specificity of non-invasive testing is lower in the presence of AS even without epicardial CAD [5].

3.1. Invasive Physiological Assessment

The assessment of ischemic burden induced by a coronary plaque in presence of severe AS remains challenging since the most commonly used pressure-wire indices including fractional flow reserve (FFR) and instantaneous wave-free ratio (iFR) may be influenced by valve hemodynamics. The accuracy of FFR relies on the achievement of maximal hyperemia, which is normally obtained in the catheterization laboratory with the intravenous or intracoronary administration of vasodilatory agents, such as adenosine. The complex interplay between the stenotic valve, elevated left ventricular end-diastolic pressure, left ventricular hypertrophy and the associated negative remodelling of the coronary microcirculation may blunt the response to adenosine and the achievement of maximal hyperaemia [25–29]. These factors may theoretically reduce the reliability of FFR in AS, causing a possible underestimation of the true ischemic significance of a given coronary obstruction.

Resting coronary flow is increased in patients with severe AS and this is the main pathophysiological element that affects coronary flow reserve (CFR) in this setting, reducing the delta between hyperemic and resting flow [30,31]. Stoller et al. investigated the
changes in CFR and microvascular resistances before, and after, TAVI. Notably, resting flow estimated by transit time using thermodilution decreased significantly after TAVI. Conversely, hyperemic transit time remained unchanged after aortic valve replacement. Consistently, index of microcirculatory resistance (IMR) did not vary after TAVI (26 U vs. 30 U, \( p = \text{ns} \)) [31]. In a multicenter retrospective analysis, the delta between resisting \( P_d/P_a \) and FFR, a surrogate for hyperaemic microvascular vasodilation, was not significantly different between severe AS, moderate AS and controls, suggesting a clinically sufficient hyperaemic response to adenosine in patients with AS [32].

An opposite trend was observed by Ahmad et al. who recently performed doppler-derived coronary flow assessment after TAVI showing that resting flow do not change after TAVI whereas hyperemic flow increased significantly. Using wave intensity analysis, they were able to demonstrate that the coronary flow during the wave-free period, and consequently the iFR, were overall not influenced by TAVI. On the contrary, hyperemic flow increased significantly after TAVI with a consistent reduction in the mean FFR value [33]. Given the discordant results of the available data, the dilemma of coronary physiology in AS remains difficult to solve. However, most of the studies are concordant in identifying four main factors that should be taken into account when interpreting the results of a physiological test in AS: (1) Resting coronary flow can be increased; (2) peak hyperaemic coronary flow can be reduced; (3) the delta between baseline flow at maximal achievable coronary flow at rest can be reduced; (4) microvascular vasodilatation can be impaired by extravascular compression forces related to the increased LV end-diastolic pressure and remodeling associated with hypertrophy and fibrosis.

The physiological alterations caused by aortic valve obstruction have recently been investigated by Yamanaka et al. comparing nuclear myocardial perfusion imaging and coronary physiology in severe AS patients. Notably, they observed a different behavior of both FFR and iFR in AS compared with standard stable CAD. In particular, the best cut-off for FFR was slightly increased compared with the standard clinical threshold (0.82 vs. 0.80) [34]. On the contrary the iFR best cut-off in detecting ischemia was significantly lower in AS (0.82 vs. 0.89). Lowering the iFR cut-off for detecting ischemia was also reported by other groups of investigators and it could be used to reduce unnecessary CAD treatment in TAVI candidates [35–38] (Table 2).

### Table 2. Invasive assessment of myocardial ischemia in patients undergoing TAVI.

| Study          | Study Design | Patients (n) | Reference Standard | Optimal FFR by ROC | Optimal iFR by ROC | Cut-Offs Tested | Sn (%) | Sp (%) | NPV (%) | PPV (%) |
|----------------|--------------|--------------|---------------------|--------------------|--------------------|-----------------|--------|--------|---------|---------|
| Scarsini et al. [36] | Prospective cohort | 28 | Adenosine SPECT | 0.78 | – | FFR < 0.78 | 87 | 88 | 92 | 81 |
| Yamanaka et al. [34] | Prospective cohort | 95 | Adenosine SPECT | 0.82 | 0.82 | iFR < 0.82 | 80 | 69 | 86 | 60 |
| Scarsini et al. [35] | Prospective cohort | 252 (85 AS) | FFR ≤ 0.80 | – | 0.83 | iFR < 0.83 | 72 | 84 | 96 | 78 |

Abbreviations: FFR, Fractional flow reserve; iFR, instantaneous wave-free ratio; ROC, Receiver operating characteristic; Sn, Sensitivity; Sp, Specificity; NPV, Negative predictive value; PPV, Positive predictive value; SPECT, Single-photon emission computed tomography; AS, aortic stenosis.

Other novel non-hyperemic pressure-wire indices may have the potential to be used to functionally assess coronary lesions in patients undergoing TAVI. However, no data are available so far and this represents an interesting field for future research [39].

### 3.2. Does Coronary Physiology Assessment Vary after TAVI?

To date, few studies have investigated the variations of physiological indices before and after aortic valve replacement. Pesarini et al. observed no overall significant variations in FFR measurement immediately before and after TAVI. Notably, a different trend was observed for coronary lesions with abnormal FFR at baseline compared to those le-
sions with FFR >0.80. In borderline or FFR-positive lesions, FFR tended to worsen after TAVI (0.71 ± 0.11 vs. 0.66 ± 0.14). Conversely, in FFR-negative lesions, FFR improved significantly (0.92 ± 0.06 vs. 0.93 ± 0.07). Overall, only 8 out of 133 lesions crossed the clinical 0.80 cut-off after TAVI [40]. Stoller et al. observed an improvement of FFR values after TAVI (0.90 ± 0.08 vs. 0.93 ± 0.08, p = 0.002), and this was related primarily to a significant decrease in hyperaemic mean aortic pressure [31]. A contemporary quantitative meta-analysis of 5 studies evaluating 250 coronary vessels in 169 patients with severe AS suggested that FFR in diseased vessels is not affected by TAVI, with a mean difference −0.01, 95% CI −0.03–0.01, p = 0.49 [41].

The variations of iFR before and after aortic valve replacement have been investigated by Scarsini et al. in a cohort of patients undergoing TAVI [42]. Overall iFR did not vary significantly before or after TAVI. However, threshold crossover was observed in up to 15% of the lesions after TAVI, shifting the indication for treatment more often compared to what observed for FFR-guided revascularization strategy [42].

Scarce data is available on the long-term variations of coronary physiology in patients undergoing aortic valve replacement. An exploratory study by Scarsini et al. in 23 coronary lesions showed that FFR decreased in 3(13%) lesions with abnormal baseline value, whereas it remained stable in lesions with FFR > 0.80; conversely, iFR did not show a systematic trend at long-term after TAVI and iFR demonstrated a higher reclassification rate at follow-up compared with FFR (p = 0.02) [43].

Conversely, Vendrik et al. reported a significant reduction of FFR values over time up to 6 months after TAVI, whereas iFR did not show significant variations at 6 months of follow up [44]. The authors concluded that using resting indices may be more appropriate to select TAVI candidates who require CAD treatment. Camuglia et al. described the variations of CFR in a small cohort of patients undergoing TAVI. CFR was measured in 8 severe AS patients at baseline, immediately after TAVI and 12 months later. Notably CFR was severely impaired at baseline in all the cases (0.65, 95% confidence interval (CI) 0.36–0.93) [45]. No significant variations were observed immediately after TAVI, a trend confirmed by Stoller et al. in a larger TAVI cohort [31]. Nonetheless, at 12-month follow up, CFR was significantly increased (2.18, 95% CI 1.88–2.47, p < 0.01) [45].

In summary, despite physiological assessment is safe and feasible in patients with untreated AS, the physiological alterations caused by the valvular obstruction can significantly impair the results. In particular, caution should be taken in the interpretation of borderline values, which should be reassessed after valve implantation.

3.3. Quantitative Flow Ratio in Presence of Aortic Stenosis

Quantitative flow ratio (QFR) (QAngioXA-3D prototype, Medis, Leiden, the Netherlands) is an angiography-based physiology software that uses thrombolysis in myocardial infarction (TIMI) frame count of a single-vessel in two orthogonal views as the surrogate marker of blood flow to calculate the translesional gradient ratio [46–49]. The diagnostic performance of QFR has been recently evaluated in patients with AS undergoing TAVI. A study performed by Hernán Mejía-Rentería et al. has enrolled 115 patients with severe AS and concomitant CAD (138 coronary arteries) who underwent FFR assessment before TAVI. The authors compared the diagnostic yield of post-hoc QFR using FFR as a reference and found that using ≤0.80 as cut-off for both techniques, QFR correctly classified the functional significance of coronary stenosis in 112 vessels (81%) [50]. Moreover, the authors showed that in patients with an aortic valvular area (AVA) ≥0.80 cm², the classification agreement between both methods was as high as 91%, and it decreased to 79% when AVA was 0.60–0.80 cm², and to 66% when AVA was <0.60 cm² (p = 0.022 for comparison between AVA ranges) [50]. Notably the diagnostic yield of QFR in this setting is lower than reported in other settings and could be related to the presence of microvascular impairment in accordance with previous studies [50], but further studies are needed.
3.4. FFR<sub>CT</sub> in Presence of Aortic Stenosis

Fractional flow reserve-computed tomography (FFR-CT) uses computational flow dynamics to simulate invasive FFR from a standard CTA acquisition, providing both anatomical and functional information. Michail et al. has recently assessed the feasibility, and validity of FFR-CT in 42 patients with AS, who underwent both CTA and conventional FFR measurement with a pressure wire (CAST-FFR study) [51]. The authors reported a strong correlation between conventional pressure wire-derived FFR and FFR-CT (AUC 0.83; 0.72–0.93, p < 0.0001) and the sensitivity, specificity, PPV and NPV were 73.9%, 78.4%, 68.0%, and 82.9%, respectively, with 76.7% diagnostic accuracy [51]. To assess the validity of FFR-CT in patients with AS will be the aim of the FORTUNA (Evaluation of Fractional Flow Reserve Calculated by Computed Tomography Coronary Angiography) trial (Clinicaltrials.gov: NCT03665389) which is a single-center, open-label, exploratory, prospective study, that will compare iFR pre-TAVI, FFR- and iFR-post TAVI with the corresponding FFRCT measurements pre and post TAVI.

4. Impact of Myocardial Revascularization in Patients Undergoing TAVI

In surgical candidates, the current guidelines suggest that myocardial revascularization with coronary artery bypass graft (CABG) at the time of surgical aortic valve replacement (SAVR) is a class I recommendation in the presence of stenoses of ≥70%, and a class IIa recommendation if the stenoses are 50–70% on angiography. This recommendation is based on small, non-randomized, retrospective studies, which showed that non-revascularised CAD patients have poorer 10-year survival rates than those undergoing revascularization or not requiring CABG [52,53]. Moreover, it is reasonable to combine the two procedures (coronary revascularization and valve replacement) whenever a major cardiac operation is planned in light of the risks related with a future redo operation. A recent meta-analysis by Kotronias et al. showed that a percutaneous transcatheter approach combing TAVI and PCI conferred similar outcomes to a surgical approach combining SAVR and CABG [54]. Therefore, patients with severe AS and CAD can have either approach determined predominantly by the surgical risk. Indeed, the 2017 ESC/EACTS Guidelines for the management of valvular heart disease suggest that PCI should be considered in the presence of coronary artery diameter stenosis >70% in proximal segments (Class IIa) with a level of evidence C [4]. As acknowledged in the guidelines, limited evidence is available and the prognostic value of bystander CAD in patients with AS remains to be established, while the potential benefits of PCI in this setting remains unclear (Figure 1).

![Figure 1. The management of CAD in TAVI patients: who need myocardial revascularization and when? Abbreviations: ACS, Acute coronary syndrome; PCI, Percutaneous coronary intervention; CAD, Coronary artery disease.](image)
4.1. Prognostic Impact of CAD in Patients Undergoing TAVI

The prognostic impact of CAD in patients undergoing TAVI is predominantly based on retrospective, single center studies, with small sample size and without a standardized definition of CAD and reported discordant results (Table 3). Some studies have demonstrated that CAD is associated with impaired clinical outcome. Dewey et al. have shown that patients with CAD had a 10.1-fold greater risk of mortality (95% CI: 2.1 to 174.8) within 30 days after TAVI procedure than those who did not. [55]. These results were further corroborated by data from the Bern TAVI and PCI registries which document an increased risk of ischemic events and cardiovascular mortality at 1-year follow-up (hazard ratio (HR) 1.86, 95% CI 1.03–3.36, \( p = 0.040 \)) [56]. Moreover, Stefanini et al. demonstrated that patients with a high preoperative SYNTAX score (Synergy Between PCI With Taxus and Cardiac Surgery, (SS)), defined as SS >22, had worse outcomes compared to the group with low SS [57]. This finding is in agreement with results from a large multi-centre study of 1270 TAVI patients that identified the same threshold of SS >22 as an independent predictor of all-cause mortality (HR 2.09; \( p = 0.017 \)) [58]. In contrast, other studies have shown neutral impact of CAD when adjusting for mortality-modifying comorbidities. The German TAVI registry showed a higher crude in-hospital mortality in patients with CAD (10.0 vs. 5.5 %, Odds ratio (OR) 1.90, 95 % CI 1.23–2.93), which was no longer significant after adjustment for confounders (adjusted OR 1.41, 95 % CI 0.85–2.33) [59]. Similar findings have been obtained by the analysis of 2588 consecutive patients from the U.K. TAVI Registry which showed that after adjusting for confounders, the presence and extent of CAD was not associated with early (30-days, \( p = 0.36 \)) or late (4 years, \( p = 0.10 \)) survival [60]. Also, in a large meta-analysis including 2472 patients, it has been observed that CAD was not a risk factor for higher mortality (OR 1.0, 95% CI 0.67–1.50) [61].

4.2. Benefits of PCI in Patients Undergoing TAVI

Despite the feasibility of PCI in severe AS patients scheduled for TAVI, the benefits of revascularization compared to optimal medical therapy remain uncertain. Previous studies comparing TAVI plus PCI versus TAVI alone have showed discordant results even when the degree of revascularization, assessed by residual SYNTAX score, was taken into account, as summarized in Table 3.

A meta-analysis conducted by Kotronias et al., including nine observational studies and 3858 patients, showed that severe AS patients that underwent revascularization with PCI had a higher rate of major vascular complications (OR 1.86; 95% CI 1.33–2.60; \( p < 0.001 \)) and higher 30-day mortality (OR 1.42; 95% CI 1.08–1.87; \( p = 0.01 \)) [62]. Moreover, there were no differences in effect estimates for 30-day cardiovascular mortality (OR: 1.03; 95% CI, 0.35–2.99), myocardial infarction (OR: 0.86; 95% CI, 0.14–5.28), acute kidney injury (OR: 0.89; 95% CI, 0.42–1.88), stroke (OR: 1.07; 95% CI, 0.38–2.97), or 1-year mortality (OR: 1.05; 95% CI, 0.71–1.56) [62]. This finding was further corroborated by the presentation of the preliminary results of the (The percutAneous Coronary inTervention prIor to transcatheter aortic VAIve implantation) ACTIVATION trial [63]. The ACTIVATION trial is [64] a prospective, multicenter study which randomized a total of 235 patients with at least 1 lesion of \( \geq 70\% \) severity in a major epicardial vessel to PCI versus conservative management prior to TAVI. The authors reported no difference in the primary endpoint of death and rehospitalization at one year (41.5% in the PCI group vs. 44% in the no-PCI group, \( p = 0.067 \)) [63]. Additionally, the study reported a higher rate of bleeding in the PCI group (44.5% vs. 28.4%, \( p = 0.02 \)) [64]. Notably, patients with history of active bleedings, recent acute coronary syndrome, left main disease, or class III-IV angina were excluded from the study.

The absence of prognostic benefit of PCI in severe AS patients undergoing TAVI is consistent with the findings of the literature on myocardial revascularization in stable CAD [65,66].

It is the opinion of the authors that a stratified approach is required to identify severe AS patients who will symptomatically and/or prognostically benefit from PCI. Further research into biomarkers and clinical pathways is required to identify patients who may
benefit the most from CAD revascularization. This is particularly important as TAVI is expanding to younger and lower risk severe AS patients with a longer life-expectancy than the high-risk severe AS patients the current body of research has so far focused on [67,68].

4.3. FFR Guided Revascularization

Current ESC guidelines on myocardial revascularization strongly recommend physiological assessment of borderline coronary lesions in patients with stable CAD [69]. On the other hand, recent ESC guidelines on management of valvular heart disease, recommend to assess CAD in patients with AS undergoing aortic valve replacement by means of angiography alone [4]. The reason for this disagreement lies in the complex pathophysiology of coronary flow in AS and the consequent exclusion of these patients from any validation or outcome trial on physiological indices [70–74]. Up to date, few data are available on the clinical outcome of FFR-guided revascularization in patients undergoing TAVI. When coronary physiology is used to guide the myocardial revascularization of patients with severe AS, it leads to an important simplification of the clinical management. Di Gioia and colleagues demonstrated that FFR allows to downgrade the number of diseased vessel compared to coronary angiography alone without increasing the adverse event rates up to 5 years (38% vs. 39%; \( p = 0.98 \)) [75]. In a retrospective observational study including 216 patients undergoing TAVI, Lunardi et al. demonstrated that FFR-guided revascularization presented a better major adverse cardiac and cerebrovascular events (MACCE)-free survival at 24 months compared with those who underwent angiography-guided revascularization (92.6% versus 82.0%; \( p = 0.035 \)). Bystander intermediate coronary lesions were FFR negative in 78.2% of cases and were safely deferred without ischemic complications during the TAVI procedure and long term [76]. To confirm these observations, a nationwide, randomized clinical trial (FAITAVI (Functional Assessment in TAVI), Clinicaltrial.gov: NCT03360591) is currently ongoing to compare FFR-guided versus angiography-guided revascularization in patients undergoing TAVI. Similarly awaited are the results of the ongoing Revascularization in Patients Undergoing Transcatheter Aortic Valve Implantation (NOTION-3) trial, comparing an FFR-guided complete revascularization with PCI versus conservative management in patients undergoing TAVI (Clinicaltrial.gov: NCT03058627).

In summary, the prognostic impact of CAD in patients with severe AS is still debated and the benefits of myocardial revascularization in patients with severe AS undergoing TAVI should be carefully evaluated by the Heart Team. The available literature recommends against routine revascularization in patient undergoing TAVI, especially in the presence of stable CAD. A multidisciplinary individualized decision should take into account patient’s age, comorbidities, the amount of myocardium at risk, and the clinical presentation. Myocardial revascularization should be considered in presence of disease involving the proximal segment of large epicardial vessel, especially in patients presenting with high-risk acute coronary syndrome where ischemia is mainly driven by plaque instability and in patients with refractory angina, even after relief of the AS.
Table 3. Prognostic impact of CAD in TAVI candidates.

| Study                  | Design      | Patients (n) | Follow-Up (Months) | Stratification | Outcome(s)                  |
|------------------------|-------------|--------------|--------------------|----------------|------------------------------|
| Lopez Otero et al.     | Retrospective cohort | 349 (187 CAD) | 35.2 (mean)        | No CAD     | MACE (p = 0.91) 39%         |
|                        |             |              |                    | rSS = 0     |                             |
|                        |             |              |                    | 0 < rSS < 8 |                             |
|                        |             |              |                    | rSS ≥ 8     |                             |
| Huczek et al.          | Registry    | 896 (462 CAD) | 1                  | No CAD     | Mortality (p = 0.14) 5.1%   |
|                        |             |              |                    | bSS < 22   |                             |
|                        |             |              |                    | bSS ≥ 22   |                             |
| Witberg et al.         | Retrospective cohort | 1270 (453 CAD) | 22.8 (median)     | No CAD     | Mortality (p < 0.001) 21.9%|
|                        |             |              |                    | bSS < 22   |                             |
|                        |             |              |                    | bSS ≥ 22   |                             |
|                        |             |              |                    | No CAD     |                             |
|                        |             |              |                    | rSS < 8    |                             |
|                        |             |              |                    | rSS > 8    |                             |
| Ryan et al.            | Prospective cohort | 402 (193 CAD) | 12                 | SS-II < 37.4 MACE (p = 0.001) 13.4% |
|                        |             |              |                    | 37.4 ≤ SS-II ≤ 44.0 |                         |
|                        |             |              |                    | SS-II > 44.0 |                           |
| Shamekhi et al.        | Prospective cohort | 666 (437 CAD) | 24.7 (mean)       | No CAD     | Mortality (p = 0.001) 26.2%|
|                        |             |              |                    | bSS < 24   |                             |
|                        |             |              |                    | bSS ≥ 24   |                             |
|                        |             |              |                    | No CAD     |                             |
|                        |             |              |                    | rSS ≤ 3    |                             |
|                        |             |              |                    | rSS > 3    |                             |
|                        |             |              |                    | 0 < SS-II ≤ 23 |                           |
|                        |             |              |                    | 23 ≤ SS-II ≤ 32 |                         |
|                        |             |              |                    | 32 ≤ SS-II ≤ 43 |                        |
|                        |             |              |                    | SS-II > 43 |                             |
| Ahad et al.            | Retrospective cohort | 70 (all CAD) | 24                 | Mean bSS = 29.0 MACE (p = 0.001) 14.9% |
| Paradis et al.         | Retrospective cohort | 377 (295 CAD) | 12                 | No CAD     | Mortality (p = 0.01) 26.8%  |
|                        |             |              |                    | bSS ≤ 23   |                             |
|                        |             |              |                    | 23 ≤ bSS ≤ 32 |                           |
|                        |             |              |                    | bSS ≥ 33   |                             |
|                        |             |              |                    | No CAD     |                             |
|                        |             |              |                    | rSS < 8    |                             |
|                        |             |              |                    | rSS ≥ 8    |                             |
| Manoly et al.          | Case series  | 4 (all CAD)  | 12 (median)       | Mean bSS = 20.6 Mortality 25% |
|                        | D’Ascenzo et al. [84] | 8334 (3994 CAD) | 12           | bSS >22 versus bSS <22 PCI with rSS <8 versus PCI not performed Mortality (p = 0.001) 26.8% MACE (p = 0.61) 16.7% |
|                        |             |              |                    | PCI with rSS <8 versus PCI not performed |                             |
|                        | Witberg et al. [85] | 3107 (1645 CAD) | 8.4–36       | High rSS versus no CAD Mortality (p < 0.01) 1.85 (1.42–2.40) |
|                        |             |              |                    | PCI with rSS <8 versus PCI not performed OR 0.34 (0.12–0.93) |
|                        |             |              |                    | PCI with rSS <8 versus PCI not performed OR 1.16 (1.03–1.31) |
|                        | Chauhan et al. [86] | 238 (99 CAD)  | 14.9 (mean)      | bSS ≤ 2 Mortality, MACE, revascularization (p = 0.27) 21.3% |
|                        |             |              |                    | 3 ≤ bSS ≤ 10 |                             |
|                        |             |              |                    | bSS ≥ 11   |                             |
| Penkalla et al.        | Prospective cohort | 40 (28 CAD)  | 12 and 60         | Mean bSS = 7.6 Mortality 41.4 and 69.6% |

J. Clin. Med. 2021, 10, 946
### Table 3. Cont.

| Study                  | Design       | Patients (n) | Follow-Up (Months) | Stratification                                                                 | Outcome(s)      |
|------------------------|--------------|--------------|--------------------|--------------------------------------------------------------------------------|-----------------|
| Kobayashi et al. [88]  | Case series  | 12 (all CAD) | Intra-hospital     | Mean bSS = 22.4                                                                | Mortality, MACE | 0%               |
| Koskinas et al. [89]   | Retrospective cohort | 577 (367 CAD) | 24                 | No CAD and cTnT                                                                | Mortality       | 11.6%            |
|                        |              |              |                    | bSS < 22 and cTnT                                                              |                 |                  |
|                        |              |              |                    | >15 × ULN                                                                      |                 |                  |
| Witberg et al. [90]    | Registry     | 287 (49 CAD) | 24                 | No CAD a                                                                      | MACE            | 16.1%            |
|                        |              |              |                    | bSS ≤ 22 b                                                                     | (p = 0.19 a-b)  | 24.4%            |
|                        |              |              |                    | No CAD a                                                                      | p = 0.002 a-c   | 75%              |
|                        |              |              |                    | cSS ≤ 63 b                                                                     | MACE            | 16.1%            |
|                        |              |              |                    | No CAD a                                                                      | (p = 0.606 a-b) | 18.7%            |
|                        |              |              |                    | 0 < rSS < 9 b                                                                  | and p = 0.001 a-c | 41.2% |
|                        |              |              |                    | rSS ≥ 9 b                                                                      | MACE            | 16.1%            |
|                        |              |              |                    | (p = 0.196 a-b)                                                               |                 |                  |
|                        |              |              |                    | and p < 0.001 a-c                                                             |                 |                  |
| O’Sullivan et al. [91] | Registry     | 108 (80 CAD) | 12                 | Mean bSS = 16.1                                                                | Mortality       | 25.1%            |
| Penkalla et al. [92]   | Cohort       | 593 (308 CAD)| 1                  | No CAD a                                                                      | Mortality       | 5.3%             |
|                        |              |              |                    | CAD, no PCI, mean bSS = 5.7                                                     | p = 0.61        | 3.9%             |
|                        |              |              |                    | CAD, PCI, mean bSS = 8.0                                                        |                 | 2.6%             |
| Khawaja et al. [93]    | Retrospective cohort | 271 (93 CAD) | 1 and 12           | No CAD a                                                                      | MACE            | 12.5%            |
|                        |              |              |                    | 0 < bSS ≤ 22 b                                                                | (p = 0.016)     | 16.1%            |
|                        |              |              |                    | 22 < bSS ≤ 32 b                                                                | 29.6%           |                  |
|                        |              |              |                    | bSS > 33                                                                      | 12.5%           |                  |
| Stefanini et al. [57]  | Registry     | 445 (287 CAD)| 12                 | No CAD a                                                                      | MACE            | 16.5%            |
|                        |              |              |                    | 0 ≤ bSS ≤ 22 b                                                                | (p = 0.043)     | 26.3%            |
|                        |              |              |                    | bSS > 22                                                                      |                 |                  |
|                        |              |              |                    | No CAD a                                                                      |                 |                  |
|                        |              |              |                    | rSS ≤ 14                                                                      |                 |                  |
|                        |              |              |                    | rSS > 14                                                                      |                 |                  |
| Van Mieghem et al. [94]| Prospective cohort | 263 (124 CAD)| 16 (median)       | rSS = 0                                                                        | Mortality       | 20.1%            |
|                        |              |              |                    | rSS > 0                                                                        | (p = 0.85)      | 22.6%            |
| Saia et al. [95]       | Prospective cohort | 540 (291 CAD)| 58 (median)       | CR                                                                             | Mortality       | 2.9%             |
|                        |              |              |                    | IR                                                                             | (p = 0.45)      | 4.6%             |
| Kleczynski et al. [96] | Cohort       | 101          | 12                 | CR                                                                             | Mortality       | 7.1%             |
|                        |              |              |                    | IR                                                                             | (p = < 0.001)   | 75%              |

Abbreviations: bSS, basal Syntax score; CAD, coronary artery disease; CR, complete revascularization; IR, incomplete revascularization; MACE, major adverse cardiac events; rSS, residual Syntax score; SS, Syntax score; PCI, Percutaneous coronary intervention. a,b,c,d, identify the subgroup.

5. Timing of Percutaneous Coronary Intervention

When coronary revascularization is indicated the optimal timing in relation to the valve intervention remains to be established and no randomized data are available (Table 4). The most widely adopted approach is to perform PCI before the implantation of the valve. Nevertheless, several studies have shown the safety and feasibility of performing both interventions during the same procedure or deferring PCI after the valve replacement.
### Table 4. Timing of PCI in relation to TAVI.

|                      | Advantages                                      | Disadvantages                                      | Preferred Clinical Scenario                           |
|----------------------|-------------------------------------------------|----------------------------------------------------|-----------------------------------------------------|
| **PCI before TAVI**  | - Improve coronary flow, preventing myocardial   | - Risk of hemodynamic collapse during PCI           | - Acute coronary syndrome                            |
|                      | ischemia during right ventricular paging        |                                                    | - Severe ostial and left main stem lesions           |
|                      | - Easy coronary cannulation                      |                                                    | - Anatomical consideration                           |
|                      |                                                  |                                                    | (type of-valve, valve-in-valve procedure)            |
| **Concomitant PCI**  | - Reduce patient discomfort                      | - Increase volume of dye                            | - Normal kidney function                             |
| and TAVI             | - Avoid second arterial access                   | Operator fatigue and X-ray exposure                | - High bleeding risk                                 |
|                      | - Reduce costs of hospitalizations               |                                                    |                                                    |
|                      | - no delays in case of rescue/bail-out strategies|                                                    |                                                    |
| **PCI post TAVI**    | - Improve hemodynamic before PCI                 | - Risk of ischemia during TAVI                     | - Complex PCI (to avoid hemodynamic instability      |
|                      | - Reliable physiological                        |                                                    | related to severe AS)                               |
|                      | assessment of CAD                               |                                                    | - Borderline CAD                                     |

Abbreviations: PCI, percutaneous coronary intervention; TAVI, transcatheter aortic valve implantation; AS, aortic stenosis; CAD, Coronary artery disease.

5.1. PCI Upstream to TAVI

TAVI at its nascency was a complex and high-risk procedure that required prolonged cardiac pacing that could induce severe hypotension and possibly worsening of myocardial ischemia in patients with CAD. Moreover, there was very limited operator experience and there were very few studies examining the feasibility of coronary cannulation following a TAVI device implantation. Due to these concerns, the most common approach has been to routinely treat significant epicardial coronary disease before valve implantation. Despite the wide adoption of this approach, it should be acknowledged that it is not supported by robust clinical evidence. Nonetheless, two important considerations should be taken into account: the risk of performing complex PCI to achieve revascularization in patients with severe AS and the theoretical increase in bleeding risk during TAVI due to the requirement for dual anti-platelet therapy following coronary stent implantation.

Limited data is available on the safety of PCI in patients with severe AS. Goel et al. showed that PCI can be performed in patients with severe symptomatic AS and CAD without an increased risk of short-term mortality compared with propensity-matched patients without AS. Nevertheless, the subgroup of patients with ejection fraction ≤30% or Society of Thoracic Surgeons score ≥10% have a significant higher 30-day mortality (respectively 5.4% versus 1.2%; p < 0.001 and 10.4% versus 0%; p < 0.001) [97]. In this subgroup of patients, who frequently undergo complex PCI requiring rotational atherectomy, adjunctive balloon aortic valvuloplasty and/or mechanical circulatory support could improve the safety profile of PCI in case of a procedural complication [98]. Kotronias et al. demonstrated that rotational atherectomy can be performed safely in patients with severe AS to modify highly calcified coronary vessels in preparation for stent implantation. Notably, the rate of complications was low and not significantly different when compared to the complications rate of a matched cohort of patients without AS [99]. Nevertheless, intraprocedural coronary complications may have a profound hemodynamic impact in the presence of untreated severe AS and require emergent rescue valve intervention (most case rescue aortic-balloon valvuloplasty) [100].

Another potential disadvantage of performing PCI before TAVI is the requirement of dual antiplatelet therapy after stent insertion that could carry an additional peri-procedural hemorrhagic risk. Van Rosendaal et al. investigated the clinical outcome of patients undergoing PCI within 30 days or >30 days before TAVI, showing a significant increase in minor vascular injury and bleeding complications after TAVI in the group who had PCI within 30 days before TAVI [101].
In summary, staged PCI before TAVI should be considered when the risks of untreated myocardial ischaemia outweigh the risks of valve replacement in itself. It is reasonable to consider PCI before TAVI in patients with acute coronary syndrome and a large area of myocardium at risk due to plaque instability, patient with critical ostial lesions which may increase the risk of coronary occlusions during TAVI or in patients with concerns regarding future access to the coronary ostia due to unfavourable aortic anulus anatomy or in case of valve-in-valve procedure. In patients with indication to revascularization but at a high risk of intra-procedural complications, adjunctive balloon aortic valvuloplasty plus/minus mechanical circulatory support could be considered to improve the safety of the PCI [98]. Notably, a novel non-occlusive balloon for balloon aortic valvuloplasty (TrueFlow™, BARD, Peripheral Vascular, Tempe, AZ, USA) has been recently approved which enable anterograde perfusion through the inner lumen during inflation and does not require rapid ventricular pacing [102].

5.2. TAVI Upstream to PCI

The strategy of performing TAVI upstream to PCI has not been largely investigated in the past due to concerns related to the safety of performing the valve implantation in patient with untreated coronary lesions. However, the improvement in technological equipment together with accurate pre-procedural planning has decreased the demand of pacing and also has reduced the overall risk of the procedure itself, allowing for the possibility for the interventionalist to safely defer coronary revascularization until after valve implantation.

Deferring myocardial revascularization until after valve implantation is advantageous as it can allow symptom evaluation and residual ischemic burden assessment free from the confounding effect of severe AS (Figure 2). Since TAVI is moving toward younger patients at intermediate-to-low surgical risk, the appropriate identification of patients who could yield maximal symptomatic and prognostic benefit is of paramount importance.

Another potential advantage of an approach based on performing TAVI upstream is to improve the hemodynamic performance of the left ventricle prior to PCI. Following relief of AS, myocardial afterload decreases, as well as myocardial oxygen consumption and cardiac output significantly increases with subsequent improvement of systemic perfusion [103]. Several studies have shown an improvement both of systolic and diastolic function of the left ventricle after TAVI [104]. The haemodynamic improvement may increase the safety of performing complex PCI, which due to high calcium burden, may require extensive lesion preparation with rotational atherectomy and prolonged balloon inflation in proximal segments of the coronary tree (Figure 3) [105,106]. Moreover, the impact of contrast administration on kidney function in patients who had undergone TAVI may be better tolerated because of the hemodynamic changes following aortic valve replacement [107]. Recently, Venturi et al. reported that contrast-induced acute kidney injury occurred less frequently in patients undergoing TAVI than in patients without AS undergoing PCI, despite a worse-risk profile (OR 0.33, 95%CI 0.19–0.58, \( p = 0.002 \)). It remains to be elucidated if the timing of PCI (before TAVI versus after TAVI) may have an impact on residual renal function in patients undergoing TAVI.

A concern about performing PCI after TAVI is the technical challenge of coronary cannulation and catheter manipulation in the presence of a TAVI prosthesis (Figure 4). The ability to access coronary ostia depends on anatomical factors such as sino-tubular junction height and width and coronary height but also on the type of prosthesis and height of implantation. Self-expanding valves have a supra-annular position above the coronary ostia that could impede coronary access especially when a neocommissure lies in front of the coronary ostium. Balloon-expandable valves have a shorter height compared to the self-expandable valves. Moreover, the stent-cells of the upper row are larger, allowing easier access to the coronary ostia. The feasibility of coronary ostia cannulation after TAVI has been recently investigated by the RE-ACCESS (Reobtain Coronary Ostia Cannulation Beyond Transcatheter Aortic Valve Stent) study [108]. This single-center, prospective, registry-based
study enrolled 300 consecutive patients undergoing TAVI using all commercially available devices and undergoing coronary angiography before, and after, TAVI. The authors found a total of 23 (7.7%) cases of unsuccessful coronary cannulation after TAVI, and this issue occurred in 22 of 23 cases with the use of Evolut R/PRO (Medtronic, Minneapolis, MN, USA) transcatheter aortic valves (17.9% versus 0.4%, \( p < 0.01 \)) \cite{108}. At multivariate analysis the combination of use of the Evolut valve, sinus of Valsalva oversizing, and depth of implantation had an excellent discrimination capability to predict unsuccessful coronary cannulation after TAVI. To account for this possible issue, technical refinements of TAVI implantation aimed at commissural alignment have been proposed. Tang et al. evaluated the impact of initial deployment orientation of the SAPIEN 3 (Edwards Lifesciences, Irvine, CA, USA), Evolut, and ACURATE-neo (Boston Scientific, Marlborough, MA, USA) TAVI valves on their final orientation and neocommissural overlap with coronary arteries \cite{109}. The authors found that the initial SAPIEN 3 orientation had no impact on alignment, whereas specific adjustment in orientations of the Evolut and ACURATE-neo improved alignment \cite{109}. Optimizing valve alignment to avoid overlap between neo-commissures and coronary ostia is essential to grant coronary artery access in case of future redo TAVI or need for PCI.

Figure 2. Functional assessment after TAVI implantation. Explanatory case showing the feasibility of performing functional assessment after valve implantation (Sapien 3, 26 mm, Edwards Lifesciences, Irvine, CA, USA) in a patient with moderate atheroma on the right coronary artery. This approach has the advantage of avoiding misleading interpretation of physiological indices in presence of Scheme 0. IMR was 14 U suggesting non inducible ischemia and preserved microvascular resistance. Below: RFR, a non-hyperemic full cycle pressure-wire based index, was 0.94 and three-dimensional (3D) quantitative coronary analysis and subsequent QFR computation was 0.89. Abbreviations: FFR, fractional flow reserve; QFR, quantitative flow ratio; IMR, index of micro-vascular resistance; RFR, resting full cycle ratio.
allowing easier access to the coronary ostia. The feasibility of coronary ostia cannulation compared with TAVI combined with PCI in terms of death (5.6% vs. 10.2%, p = 0.24), major 

Figure 3. PCI with rotational atherectomy and stenting after TAVI (Edwards Sapien 3). (A) Coronary angiography after selective cannulation of left coronary artery showed severe calcific lesion of the mid left anterior descending. (B) Rotational atherectomy. (C) Predilation of the lesion with non-compliant balloon. (D) Final result after stent implantation.

Figure 4. Feasibility of coronary access post TAVI. Coronary angiography performed after TAVI thorough the CoreValve Evolut R struts. (A) Right coronary artery selective cannulation using a Judkins right catheter (JR 4, Cordis Corporation, Bridgewater, NJ, USA); (B) Left coronary artery selective cannulation with an extra backup support catheter (EBU 3.5, Medtronic Inc., Minneapolis, MN, USA).
5.3. PCI and Concomitant TAVI

Whatever the chosen approach (TAVI or PCI first) several studies have shown the feasibility and safety of performing the two procedures within the same session. The potential advantages of this approach are: (i) No requirement for additional vascular access, (ii) lower theoretical risk of vascular complications, (iii) lower patient’s inconvenience and discomfort and iv) reduction in healthcare resources utilization. Ochiai et al. found that the timing of PCI either before TAVI ($n = 143$), concomitantly with TAVI ($n = 77$), or until after TAVI ($n = 38$) was not associated with 2-year major adverse cardiac and cerebrovascular events rate (concomitant vs. pre-TAVI, HR: 0.92; 95% CI: 0.52 to 1.66; $p = 0.79$; post- vs. pre-TAVI, HR: 0.45; 95% CI: 0.18 to 1.16; $p = 0.10$) [110]. Wenaweser et al. showed that the clinical outcome at 30 days was similar for patients undergoing isolated TAVI as compared with TAVI combined with PCI in terms of death (5.6% vs. 10.2%, $p = 0.24$), major stroke (4.1% vs. 3.4%, $p = 1.00$), and the VARC combined safety endpoint (31.0% vs. 23.7%, $p = 0.33$) [111]. More recently, Barbanti et al. confirmed that patients undergoing TAVI and PCI in the same setting had similar rate of the composite of death, disabling stroke, and myocardial infarction when compared with patients without CAD, and patients with severe CAD left untreated (TAVI + PCI: 10.4%; severe CAD left untreated: 15.4%; no-CAD: 14.8%; $p = 0.765$) [112].

A possible disadvantage of concomitant TAVI and PCI strategy is the amount of contrast media administered at the time of the procedure. Penkalla et al. noticed that radiation time and the amount of contrast agent were higher during combined treatment compared to a staged PCI strategy. This could translate into a higher risk of acute kidney injury, especially in patient with chronic renal disease, undergoing complex PCI. A recent meta-analysis, based on observational data comparing the short-term safety outcomes of concomitant versus staged PCI with TAVI in severe AS patients, demonstrated that the 30-day all-cause mortality and other major safety endpoints did not significantly differ between the two approaches [113]. Notably, the pooled rate of renal failure was not statistically different between the two groups, although the incidence was relatively higher in the concomitant PCI and TAVI group (5% versus 2.2%) [113]. Another disadvantage of combining two procedure in the same session is the increased of the procedural complexity as well as the operator fatigue.

6. Conclusions

Coronary artery disease is highly prevalent in patients with severe AS and frequently poses a clinical management challenge. The complex pathophysiology of coronary flow in AS makes the interpretation of symptoms, as well as the assessment of myocardial ischemia challenging. Although the prognostic impact of CAD in patients undergoing TAVI is still debated, the treatment of angiographic significant stable coronary stenosis with PCI seems to have no prognostic benefits. Conversely treatment of unstable coronary disease is still likely to retain a clinical benefit in candidates to TAVI. The benefits and timing of myocardial revascularization in patients with severe AS undergoing TAVI should be carefully evaluated by the Heart Team and decisions individualised. Going forward, a stratified medicine approach will likely be required to identify severe AS patients who will symptomatically and/or prognostically benefit from PCI. Since TAVI is moving towards younger and lower risk patients, further research into biomarkers and clinical pathways is warranted to identify patients with severe AS who may benefit the most from myocardial revascularization.

Author Contributions: Conceptualization, F.M., R.S., M.K.B., R.A.K. and A.P.B.; writing—original draft preparation, F.M., R.S., M.K.B. and R.A.K.; writing—review and editing, F.M., R.S., M.K.B., R.A.K., D.T.P., J.J.B., J.L.C., G.V. and M.P.; supervision, G.L.D.M. and A.P.B. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Leon, M.B.; Smith, C.R.; Mack, M.J.; Makkar, R.R.; Svensson, L.G.; Kodali, S.K.; Thourani, V.H.; Tuzcu, E.M.; Miller, D.C.; Herrmann, H.C.; et al. Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients. N. Engl. J. Med. 2016, 374, 1609–1620. [CrossRef] [PubMed]

2. Reardon, M.J.; Van Mieghem, N.M.; Popma, J.J.; Kleiman, N.S.; Søndergaard, L.; Mumtaz, M.; Adams, D.H.; Deeb, G.M.; Maini, B.; Gada, H.; et al. Surgical or Transcatheter Aortic-Valve Replacement in Intermediate-Risk Patients. N. Engl. J. Med. 2017, 376, 1321–1331. [CrossRef] [PubMed]

3. Chen, H.Y.; Dufresne, L.; Burr, H.; Ambikkumar, A.; Yasui, N.; Luk, K.; Ranatunga, D.K.; Whitmer, R.A.; Lathrop, M.; Engert, J.C.; et al. Association of LPA Variants With Aortic Stenosis: A Large-Scale Study Using Diagnostic and Procedural Data From Electronic Health Records. JAMA Cardiol. 2018, 3, 129–139. [CrossRef] [PubMed]

4. Baumgartner, H.; Falk, V.; Meding, J.B.; Torzewski, J.; Voigt, P.A.; Skoda, R.C.; Hamm, C.W.; et al. 2017 ESC/EACTS Guidelines for the management of valvular heart disease. Eur. Heart J. 2017, 38, 2739–2791. [CrossRef]

5. Danson, E.; Hansen, P.; Sen, S.; Davies, J.; Meredith, I.; Bhindi, R. Assessment, treatment, and prognostic implications of CAD in patients undergoing TAVI. Nat. Rev. Cardiol. 2016, 13, 276–285. [CrossRef]

6. Di Gioia, G.; Scarsini, R.; Strisciuglio, T.; De Biase, C.; Zivelonghi, C.; Franco, D.; De Bruyne, B.; Ribichini, F.; Barbato, E. Correlation between Angiographic and Physiologic Evaluation of Coronary Artery Narrowings in Patients With Aortic Valve Stenosis. Am. J. Cardiol. 2017, 120, 106–110. [CrossRef]

7. van den Boogert, T.P.; Vendrik, J.; Claessen, B.E.P.M.; Baan, J.; Beijk, M.A.; Limpens, J.; Boekholdt, S.A.M.; Hoek, R.; Planken, R.N.; Henriques, J.P. CTCA for detection of significant coronary artery disease in routine TAVI work-up: A systematic review and meta-analysis. Neth. Heart J. 2018, 26, 116–127. [CrossRef] [PubMed]

8. Andreini, D.; Pontone, G.; Mushtaq, S.; Bartorelli, A.L.; Ballerini, G.; Bertella, E.; Segurini, C.; Conte, E.; Annoni, A.; Bagggiano, A.; et al. Diagnostic accuracy of multidetector computed tomography coronary angiography in 325 consecutive patients referred for transcatheter aortic valve replacement. J. Heart Valve Dis. 2014, 23, 50–55. [CrossRef] [PubMed]

9. Hamdan, A.; Wellnhof, E.; Konen, E.; Kelle, S.; Goitein, O.; Andrada, B.; Raanani, E.; Segev, A.; Barbash, I.; Klempern, R.; et al. Coronary CT angiography for the prior to coronary artery stenosis in patients referred for transcatheter aortic valve replacement. J. Cardiovasc. Comput. Tomogr. 2018, 9, 31–41. [CrossRef]

10. Opolski, M.P.; Kim, W.K.; Liebetrau, C.; Walther, C.; Blumenstein, J.; Gaede, L.; Kempfert, J.; Van Linden, A.; Walther, T.; Hamm, C.W.; et al. Diagnostic accuracy of computed tomography angiography for the detection of coronary artery disease in patients referred for transcatheter aortic valve implantation. Clin. Res. Cardiol. 2015, 104, 471–480. [CrossRef]

11. Matsumoto, S.; Yamada, Y.; Hashimoto, M.; Okamura, T.; Yamada, M.; Yashima, F.; Hayashida, K.; Fukuoda, K.; Jainzaki, M. CT imaging before transcatheter aortic valve implantation (TAVI) using variable helical pitch scanning and its diagnostic performance for coronary artery disease. Eur. Radiol. 2017, 27, 1963–1970. [CrossRef]

12. Rossi, A.; De Cecco, C.N.; Kennon, S.O.; Zou, L.; Meinel, F.G.; Toscano, W.; Segreto, S.; Achenbach, S.; Hausleiter, J.; Schoepf, U.J.; et al. CT angiography to evaluate coronary artery disease and revascularization requirement before transcatheter aortic valve replacement. J. Cardiovasc. Comput. Tomogr. 2017, 11, 338–346. [CrossRef] [PubMed]

13. Strong, C.; Ferreira, A.; Teles, R.C.; Mendes, G.; Abecasis, J.; Cardoso, G.; Guerreiro, S.; Freitas, P.; Santos, A.C.; Saraiva, C.; et al. Diagnostic accuracy of computed tomography angiography for the exclusion of coronary artery disease in candidates for transcatheter aortic valve implantation. Sci. Rep. 2019, 9, 19942. [CrossRef] [PubMed]

14. Chakriangkrai, K.; Jhu, H.Y.; Shantha, G.P.S.; Abdulkhak, A.B.; Tandon, R.; Alqasrawi, M.; Klappa, A.; Pancholy, S.; Deshmukh, A.; Bhama, J.; et al. Diagnostic Accuracy of Coronary Computed Tomography Before Aortic Valve Replacement: Systematic Review and Meta-Analysis. J. Thorac. Imaging 2018, 33, 207–216. [CrossRef] [PubMed]

15. Annoni, A.D.; Andreini, D.; Pontone, G.; Mancini, M.E.; Formenti, A.; Mushtaq, S.; Bagggiano, A.; Conte, E.; Guglielmo, M.; Muscogiuri, G.; et al. CT angiography prior to TAVI procedure using variable helical pitch scanning and its diagnostic performance for coronary artery disease. Eur. Radiol. 2017, 27, 1963–1970. [CrossRef]

16. Harris, L.L.; De Cecco, C.N.; Schoepf, U.J.; Steinberg, D.H.; Bayer, R.R.; Krazinski, A.W.; Dyer, K.T.; Sandhu, M.K.; Zile, M.R.; Meinel, F.G. Dual-source CT imaging to plan transcatheter aortic valve replacement: Accuracy for diagnosis of obstructive coronary artery disease. Radiology 2015, 275, 80–88. [CrossRef]

17. Cieffo, A.; Giustino, G.; Spagnolo, P.; Panoulas, V.F.; Montorfano, M.; Latib, A.; Fijini, F.; Agricola, E.; Gerli, C.; Franco, A.; et al. Routine Screening of Coronary Artery Disease With Computed Tomographic Coronary Angiography in Place of Invasive Coronary Angiography in Patients Undergoing Transcatheter Aortic Valve Replacement. Circ. Cardiovasc. Interv. 2015, 8, e002025. [CrossRef]

18. Joseph, J.; Kotronias, R.A.; Estrin-Serlui, T.; Cahill, T.J.; Kharbanda, R.K.; Newton, J.D.; Grebenik, C.; Dawkins, S.; Banning, A.P. Safety and operational efficiency of restructuring and redeploying a transcatheter aortic valve replacement service during the COVID-19 pandemic: The Oxford experience. Cardiovasc. Revasc. Med. 2020. [CrossRef]

19. Nishimura. R.A.; Otto, C.M.; Bonow, R.O.; Carabello, B.A.; Erwin, J.P.; Guyton, R.A.; O’Gara, P.T.; Ruiz, C.E.; Skubas, N.J.; Sorajja, P.; et al. 2014 AHA/ACC Guideline for the Management of Patients With Valvular Heart Disease: Executive summary: A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. Circulation 2014, 129, 2440–2492. [CrossRef]
20. Vandeplas, A.; Willems, J.L.; Piessens, J.; De Geest, H. Frequency of angina pectoris and coronary artery disease in severe isolated valvular aortic stenosis. Am. J. Cardiol. 1988, 62, 117–120. [CrossRef]

21. Julius, B.K.; Spillmann, M.; Vassalli, G.; Villari, B.; Eberli, F.R.; Hess, O.M. Angina pectoris in patients with aortic stenosis and normal coronary arteries. Mechanisms and pathophysiological concepts. Circulation 1997, 95, 892–898. [CrossRef]

22. Marcus, M.L.; Doty, D.B.; Hiratzka, L.F.; Wright, C.B.; Eastham, C.L. Decreased coronary reserve: A mechanism for angina pectoris in patients with aortic stenosis and normal coronary arteries. N. Engl. J. Med. 1982, 307, 1362–1366. [CrossRef] [PubMed]

23. Ahmed, J.H.; Kim, S.M.; Park, S.J.; Jeong, D.S.; Woo, M.A.; Jung, S.H.; Lee, S.C.; Park, S.W.; Choe, Y.H.; Park, P.W.; et al. Coronary Microvascular Dysfunction as a Mechanism of Angina in Severe AS: Prospective Adenosine-Stress CMR Study. J. Am. Coll. Cardiol. 2016, 67, 1412–1422. [CrossRef] [PubMed]

24. Gould, K.L.; Carabello, B.A. Why angina in aortic stenosis with normal coronary arteriograms? Circulation 2003, 107, 3121–3123. [CrossRef]

25. Rajappan, K.; Rimoldi, O.E.; Dutka, D.P.; Ariff, B.; Pennell, D.J.; Sheridan, D.J.; Camici, P.G. Mechanisms of coronary microcirculatory dysfunction in patients with aortic stenosis and angiographically normal coronary arteries. Circulation 2002, 105, 470–476. [CrossRef] [PubMed]

26. Rajappan, K.; Rimoldi, O.E.; Camici, P.G.; Bellenger, N.G.; Pennell, D.J.; Sheridan, D.J. Functional changes in microcirculation after valve replacement in patients with aortic stenosis. Circulation 2003, 107, 3170–3175. [CrossRef]

27. Broyd, C.J.; Sen, S.; Mikhail, G.W.; Francis, D.P.; Mayet, J.; Davies, J.E. Myocardial ischemia in aortic stenosis: Insights from arterial pulse-wave dynamics after percutaneous aortic valve replacement. Trends Cardiovasc. Med. 2013, 23, 185–191. [CrossRef] [PubMed]

28. Davies, J.E.; Sen, S.; Broyd, C.; Hadjiloizou, N.; Baksi, J.; Francis, D.P.; Foale, R.A.; Parker, K.H.; Hughes, A.D.; Chukwuemeka, A.; et al. Arterial pulse wave dynamics after percutaneous aortic valve replacement: Fall in coronary diastolic suction with increasing heart rate as a basis for angina symptoms in aortic stenosis. Circulation 2011, 124, 1565–1572. [CrossRef]

29. Benenati, S.; De Maria, G.L.; Scarsini, R.; Porto, I.; Invasive “in the cath-lab” assessment of myocardial ischemia in patients with coronary artery disease: When does the gold standard not apply? Cardiovasc. Revasc. Med. 2018, 19, 362–372. [CrossRef] [PubMed]

30. Eberli, F.R.; Ritter, M.; Schwitter, J.; Bortone, A.; Schneider, J.; Hess, O.M.; Krakenbuehl, H.P. Coronary reserve in patients with aortic valve disease before and after successful aortic valve replacement. Eur. Heart J. 1991, 12, 127–138. [CrossRef]

31. Stoller, M.; Groelker, S.; Zbinden, R.; Tueller, D.; Eberli, F.; Windecker, S.; Wenaweser, P.; Seiler, C. Left ventricular afterload reduction by transcatheter aortic valve implantation in severe aortic stenosis and its prompt effects on comprehensive haemodynamics. EuroIntervention 2018, 14, 166–173. [CrossRef]

32. Scarsini, R.; De Maria, G.L.; Di Gioia, G.; Kotronias, R.A.; Aurigemma, C.; Zimbardo, G.; Burzotta, F.; Leone, A.M.; Pesarini, G.; Trani, C.; et al. The Influence of Aortic Valve Obstruction on the Hyperemic Intracoronary Physiology: Difference Between Resting Pd/Pa and FFR in Aortic Stenosis. J. Cardiovasc. Transl. Res. 2019, 12, 539–550. [CrossRef]

33. Ahmad, Y.; Götzberg, M.; Cook, C.; Howard, J.P.; Malik, I.; Mikhail, G.; Frame, A.; Petracco, R.; Rajkumar, C.; Demir, O.; et al. Coronary Hemodynamics in Patients With Severe Aortic Stenosis and Coronary Artery Disease Undergoing Transcatheter Aortic Valve Replacement: Implications for Clinical Indices of Coronary Stenosis Severity. JACC Cardiovasc. Interv. 2018, 11, 2019–2031. [CrossRef] [PubMed]

34. Yamanaka, F.; Shishido, K.; Ochiai, T.; Moriyama, N.; Yamazaki, K.; Sugitani, A.; Tani, T.; Tobita, K.; Mizuno, S.; Tanaka, Y.; et al. Instantaneous Wave-Free Ratio for the Assessment of Intermediate Coronary Artery Stenosis in Patients With Severe Aortic Valve Stenosis: Comparison With Myocardial Perfusion Scintigraphy. JACC Cardiovasc. Interv. 2018, 11, 2032–2040. [CrossRef] [PubMed]

35. Scarsini, R.; Pesarini, G.; Zivelonghi, C.; Piccoli, A.; Ferrero, V.; Lunardi, M.; Barbierato, M.; Caprioglio, F.; Vassanelli, C.; Ribichini, F. Coronary physiology in patients with severe aortic stenosis: Comparison between fractional flow reserve and instantaneous wave-free ratio. Int. J. Cardiol. 2017, 243, 40–46. [CrossRef] [PubMed]

36. Scarsini, R.; Cantone, R.; Venturi, G.; De Maria, G.L.; Vario A.; Braggio, P.; Lunardi, M.; Pesarini, G.; Ferdeghini, M.; Piccoli, A.; et al. Correlation between intracoronary physiology and myocardial perfusion imaging in patients with severe aortic stenosis. Int. J. Cardiol. 2019, 292, 162–165. [CrossRef] [PubMed]

37. Ahmad, Y.; Vendrik, J.; Eftekhar, A.; Howard, J.P.; Cook, C.; Rajkumar, C.; Malik, I.; Mikhail, G.; Ruparelia, N.; Hadjiloizou, N.; et al. Determining the Predominant Lesion in Patients With Severe Aortic Stenosis and Coronary Stenoses: A Multicenter Study Using Intracoronary Pressure and Flow. Circ. Cardiovasc. Interv. 2019, 12, e008263. [CrossRef]

38. Scarsini, R.; Persarin, G.; Lunardi, M.; Piccoli, A.; Zivelonghi, C.; Cantone, R.; Bellamoli, M.; Ferrero, V.; Gottin, L.; Faggian, G.; et al. Observations from a real-time, iFR-FFR “hybrid approach” in patients with severe aortic stenosis and coronary artery disease undergoing TAVI. Cardiovasc. Revasc. Med. 2019, 18, 355–359. [CrossRef]

39. De Maria, G.L.; Garcia-Garcia, H.M.; Scarsini, R.; Hideo-Kajita, A.; Gonzalo Lopez, N.; Leone, A.M.; Sarno, G.; Daemen, J.; Shlomfizz, E.; Jeremias, A.; et al. Novel Indices of Coronary Physiology: Do We Need Alternatives to Fractional Flow Reserve? Circ. Cardiovasc. Interv. 2020, 13, e008487. [CrossRef] [PubMed]

40. Pesarini, G.; Scarsini, R.; Zivelonghi, C.; Piccoli, A.; Gambaro, A.; Gottin, L.; Rossi, A.; Ferrero, V.; Vassanelli, C.; Ribichini, F. Functional Assessment of Coronary Artery Disease in Patients Undergoing Transcatheter Aortic Valve Implantation: Influence of Pressure Overload on the Evaluation of Lesions Severity. Circ. Cardiovasc. Interv. 2016, 9. [CrossRef] [PubMed]
41. Kotronias, R.A.; Scarsini, R.; Rajasundaram, S.; De Maria, G.L.; Ciofani, J.L.; Ribichini, F.; Kharbanda, R.K.; Banning, A.P. Transcatheter Aortic Valve Replacement Influence on Coronary Hemodynamics: A Quantitative Meta-Analysis and Proposed Decision-Making Algorithm. J. Invasive Cardiol. 2020, 32, 37–40.

42. Scarsini, R.; Pesarini, G.; Zivelonghi, C.; Piccoli, A.; Ferrero, V.; Lunardi, M.; Gottin, L.; Gianetti, A.; Faggian, G.; Ribichini, F. Physiologic Evaluation of Coronary Lesions Using Instantaneous Wave-free Ratio (iFR) in Patients With Severe Aortic Stenosis Undergoing Trans-catheter Aortic Valve Implantation. EuroIntervention 2017. [CrossRef]

43. Scarsini, R.; Lunardi, M.; Venturi, G.; Pighi, M.; Tavella, D.; Pesarini, G.; Ribichini, F. Long-term variations of FFR and iFR after transcatheter aortic valve implantation. Int. J. Cardiol. 2020, 317, 37–41. [CrossRef] [PubMed]

44. Vendrik, J.; Ahmad, Y.; Eftekhar, A.; Howard, J.P.; Wijntjens, G.W.M.; Stegehuis, W.E.; Cook, C.; Terkelsen, C.J.; Christiansen, E.H.; Koch, K.T.; et al. Long-Term Effects of Transcatheter Aortic Valve Implantation on Coronary Hemodynamics in Patients With Concomitant Coronary Artery Disease and Severe Aortic Stenosis. J. Am. Heart Assoc. 2020, 9, e015133. [CrossRef] [PubMed]

45. Camuglia, A.C.; Syed, J.; Garg, P.; Kaiii, B.; Chu, M.W.; Jones, P.M.; Bainbridge, D.; Teefy, P.J. Invasively assessed coronary flow dynamics improve following relief of aortic stenosis with transcatheter aortic valve implantation. J. Am. Coll. Cardiol. 2014, 63, 1808–1809. [CrossRef]

46. Tu, S.; Westra, J.; Yang, J.; von Birgelen, C.; Ferrara, A.; Pellicano, M.; Nef, H.; Tebaldi, M.; Murasato, Y.; Lansky, A.; et al. Diagnostic Accuracy of Fast Computational Approaches to Derive Fractional Flow Reserve from Diagnostic Coronary Angiography: The International Multicenter FAVOR Pilot Study. JACC Cardiovasc. Interv. 2016, 9, 2024–2035. [CrossRef]

47. Westra, J.; Andersen, B.K.; Campo, G.; Matsuo, H.; Koltowski, L.; Eftekhar, A.; Liu, T.; Di Serafino, L.; Di Girolamo, D.; Escaned, J.; et al. Diagnostic Performance of In-Procedure Angiography-Derived Quantitative Flow Reserve Compared to Pressure-Derived Fractional Flow Reserve: The FAVOR II Europe-Japan Study. J. Am. Heart Assoc. 2018, 7. [CrossRef]

48. Xu, B.; Tu, S.; Qiao, S.; Qu, X.; Chen, Y.; Yang, J.; Guo, L.; Sun, Z.; Li, Z.; Tian, F.; et al. Diagnostic Accuracy of Angiography-Based Quantitative Flow Ratio Measurements for Online Assessment of Coronary Stenosis. J. Am. Coll. Cardiol. 2017, 70, 3077–3087. [CrossRef]

49. Westra, J.; Tu, S.; Campo, G.; Qiao, S.; Matsuo, H.; Qu, X.; Koltowski, L.; Chang, Y.; Liu, T.; Yang, J.; et al. Diagnostic performance of quantitative flow ratio in prospectively enrolled patients: An individual patient-data meta-analysis. Catheter. Cardiovasc. Interv. 2019, 94, 693–701. [CrossRef]

50. Mejía-Rentería, H.; Nombela-Franco, L.; Paradis, J.M.; Lunardi, M.; Lee, J.M.; Amat-Santos, I.J.; Veiga Fernandez, G.; Kalra, A.; Bansal, E.J.; de la Torre Hernandez, J.M.; et al. Angiography-based quantitative flow ratio versus fractional flow reserve in patients with coronary artery disease and severe aortic stenosis. EuroIntervention 2020, 16, e285–e292. [CrossRef]

51. Michail, M.; Ibdahyid, A.R.; Comella, A.; Thakur, U.; Cameron, J.D.; McCormick, L.M.; Gooley, R.P.; Nicholls, S.J.; Mathur, A.; Hughes, A.D.; et al. Feasibility and Validity of Computed Tomography-Derived Fractional Flow Reserve in Patients With Severe Aortic Stenosis: The CAST-FFR Study. Circ. Cardiovasc. Interv. 2020. [CrossRef]

52. Czer, L.S.; Gray, R.J.; Stewart, M.E.; De Robertis, M.; Chaux, A.; Matloff, J.M. Reduction in sudden late death by concomitant revascularization with aortic valve replacement. J. Thorac. Cardiovasc. Surg. 1988, 95, 390–401. [CrossRef]

53. Iung, B.; Drissi, M.F.; Michel, P.L.; de Pamphilis, O.; Tsezana, R.; Cormier, B.; Vahanian, A.; Acar, J. Prognosis of valve replacement influence on coronary artery disease: A quantitative study. J. Heart Valve Dis. 2015, 24, 430–439. [PubMed]

54. Kotronias, R.A.; Bray, J.H.; Scarsini, R.; Rajasundaram, S.; Terentes-Printzios, D.; De Maria, G.L.; Kharbanda, R.K.; Mamas, M.A.; Bagur, R.; Banning, A.P. Transcatheter aortic valve replacement and percutaneous coronary intervention versus surgical aortic valve replacement and coronary artery bypass grafting in patients with severe aortic stenosis and concomitant coronary artery disease: A systematic review and meta-analysis. Catheter. Cardiovasc. Interv. 2020, 96, 1113–1125. [CrossRef] [PubMed]

55. Dewey, T.M.; Brown, D.L.; Herbert, M.A.; Culica, D.; Smith, C.R.; Leon, M.B.; Svensson, L.G.; Tuzcu, M.; Webb, J.G.; Cribier, A.; et al. Effect of concomitant coronary artery disease on procedural and late outcomes of transcatheter aortic valve implantation. Ann. Thorac. Surg. 2010, 89, 758–767; discussion 767. [CrossRef]

56. Franszone, A.; Stortecky, S.; Räber, L.; Heg, D.; Yamaji, K.; Piccolo, R.; Asami, M.; Lanz, J.; Praz, F.; Koskinas, K.; et al. Effects of coronary artery disease in patients undergoing transcatheter aortic valve implantation: A study of age- and gender-matched cohorts. Int. J. Cardiol. 2017, 243, 150–155. [CrossRef]

57. Stefanini, G.G.; Stortecky, S.; Cao, D.; Rat-Wirtzler, J.; O'Sullivan, C.J.; Gloeckler, S.; Buellesfeld, L.; Khattab, A.A.; Nielisch, P.; Pilgrim, T.; et al. Coronary artery disease severity and aortic stenosis: Clinical outcomes according to SYNTAX score in patients undergoing transcatheter aortic valve implantation. Eur. Heart J. 2014, 35, 2530–2540. [CrossRef] [PubMed]

58. Witberg, G.; Regev, E.; Chen, S.; Assali, A.; Barbash, I.M.; Planer, D.; Vaknin-Assa, H.; Guetta, V.; Yukasinovic, V.; Orvin, K.; et al. The Prognostic Effects of Coronary Disease Severity and Completeness of Revascularization on Mortality in Patients Undergoing Transcatheter Aortic Valve Replacement. JACC Cardiovasc. Interv. 2017, 10, 1428–1435. [CrossRef]

59. Abdel-Wahab, M.; Zahn, R.; Horack, M.; Gerckens, U.; Schulter, G.; Sievert, H.; Naber, C.; Voehringer, M.; Schäfer, U.; Senges, J.; et al. Transcatheter aortic valve implantation in patients with and without concomitant coronary artery disease: Comparison of characteristics and early outcome in the German multicenter TAVI registry. Clin. Res. Cardiol. 2012, 101, 973–981. [CrossRef]

60. Snow, T.M.; Ludman, P.; Banya, W.; DeBelder, M.; MacCarthy, P.M.; Davies, S.W.; Di Mario, C.; Moat, N.E. Management of concomitant coronary artery disease in patients undergoing transcatheter aortic valve implantation: The United Kingdom TAVI Registry. Int. J. Cardiol. 2015, 199, 253–260. [CrossRef]
101. van Rosendael, P.J.; van der Kley, F.; Kamperidis, V.; Katsanos, S.; Al Amri, I.; Regeer, M.; Schalij, M.J.; Ajmone Marsan, N.; Bax, J.J.; Delgado, V. Timing of staged percutaneous coronary intervention before transcatheter aortic valve implantation. *Am. J. Cardiol.* 2015, 115, 1726–1732. [CrossRef]

102. Schneeberger, Y.; Schaefer, A.; Schofer, N.; Silaschi, M.; Deuschl, F.; Blankenberg, S.; Reichenspurner, H.; Treede, H.; Schäfer, U.; Charitos, E.I.; et al. Transcatheter aortic valve implantation utilizing a non-occlusive balloon for predilatation. *Int. J. Cardiol.* 2019, 275, 65–69. [CrossRef]

103. Tsuchiya, S.; Matsumoto, Y.; Suzuki, H.; Takanami, K.; Kikuchi, Y.; Takahashi, J.; Miyata, S.; Tomita, N.; Kumagai, K.; Taki, Y.; et al. Transcatheter aortic valve implantation and cognitive function in elderly patients with severe aortic stenosis. *EuroIntervention* 2020, 15, e1580–e1587. [CrossRef]

104. Muratori, M.; Fusini, L.; Tamborini, G.; Gripari, P.; Delgado, V.; Marsan, N.A.; Ghulam Ali, S.; Barbier, P.; Bartorelli, A.L.; Alamanni, F.; et al. Sustained favourable haemodynamics 1 year after TAVI: Improvement in NYHA functional class related to improvement of left ventricular diastolic function. *Eur. Heart J. Cardiovasc. Imaging* 2016, 17, 1269–1278. [CrossRef]

105. De Maria, G.L.; Scarsini, R.; Banning, A.P. Management of Calcific Coronary Artery Lesions: Is it Time to Change Our Interventional Therapeutic Approach? *JACC Cardiovasc. Interv.* 2019, 12, 1465–1478. [CrossRef]

106. Lunardi, M.; Pighi, M.; Tamborini, G.; Gripari, P.; Delgado, V.; Marsan, N.A.; Ghulam Ali, S.; Barbier, P.; Bartorelli, A.L.; Alamanni, F.; et al. Sustained favourable haemodynamics 1 year after TAVI: Improvement in NYHA functional class related to improvement of left ventricular diastolic function. *Eur. Heart J. Cardiovasc. Imaging* 2016, 17, 1269–1278. [CrossRef]

107. Venturi, G.; Pighi, M.; Pesarini, G.; Ferrero, V.; Lunardi, M.; Castaldi, G.; Setti, M.; Benini, A.; Scarsini, R.; Ribichini, F.L. Contrast-Induced Acute Kidney Injury in Patients Undergoing TAVI Compared With Coronary Interventions. *J. Am. Heart Assoc.* 2020, 9, e017194. [CrossRef]

108. Barbanti, M.; Costa, G.; Picci, A.; Criscione, E.; Reddavid, C.; Valvo, R.; Todaro, D.; Deste, W.; Condorelli, A.; Scalia, M.; et al. Coronary Cannulation After Transcatheter Aortic Valve Replacement: The RE-ACCESS Study. *JACC Cardiovasc. Interv.* 2020, 13, 2542–2555. [CrossRef] [PubMed]

109. Tang, G.H.L.; Zaid, S.; Fuchs, A.; Yamabe, T.; Yazdchi, F.; Gupta, E.; Ahmad, H.; Kofood, K.F.; Goldberg, J.B.; Undemir, C.; et al. Alignment of Transcatheter Aortic-Valve Neo-Commissures (ALIGN TAVR): Impact on Final Valve Orientation and Coronary Artery Overlap. *JACC Cardiovasc. Interv.* 2020, 13, 1030–1042. [CrossRef] [PubMed]

110. Ochiai, T.; Yoon, S.H.; Flint, N.; Sharma, R.; Chakravarty, T.; Kaewkes, D.; Patel, V.; Nakamura, M.; Cheng, W.; Makkar, R. Timing and Outcomes of Percutaneous Coronary Intervention in Patients Who Underwent Transcatheter Aortic Valve Implantation. *Am. J. Cardiol.* 2020, 125, 1361–1368. [CrossRef] [PubMed]

111. Wenaweser, P.; Pilgrim, T.; Guerios, E.; Stortecky, S.; Huber, C.; Khattab, A.A.; Kadner, A.; Buelsfeld, L.; Gloekler, S.; Meier, B.; et al. Impact of coronary artery disease and percutaneous coronary intervention on outcomes in patients with severe aortic stenosis undergoing transcatheter aortic valve implantation. *EuroIntervention* 2011, 7, 541–548. [CrossRef]

112. Barbanti, M.; Todaro, D.; Costa, G.; Pilato, G.; Picci, A.; Gulino, S.; Capranzano, P.; La Spina, K.; Di Simone, E.; D’Arrigo, P.; et al. Optimized Screening of Coronary Artery Disease With Invasive Coronary Angiography and Ad Hoc Percutaneous Coronary Intervention During Transcatheter Aortic Valve Replacement. *Circ. Cardiovasc. Interv.* 2017, 10. [CrossRef] [PubMed]

113. Yang, Y.; Huang, F.Y.; Huang, B.T.; Xiong, T.Y.; Pu, X.B.; Chen, S.J.; Chen, M.; Feng, Y. The safety of concomitant transcatheter aortic valve replacement and percutaneous coronary intervention: A systematic review and meta-analysis. *Medicine* 2017, 96, e8919. [CrossRef] [PubMed]